A Study of Caspofungin, Liposomal Amphotericin B or the Combination of Both for Patients After Stem-Cell Transplantation
Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The study compares the safety, efficacy and pharmacokinetics of caspofungin, liposomal
amphotericin B or the combination of both in the antifungal treatment of adult patients after
allogeneic haematopoietic stem-cell transplantation with granulocytopenia and persistent i.g.
recurrent fever under adequate antibacterial therapy.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital Muenster
Collaborators:
Gilead Sciences Merck Sharp & Dohme Corp.
Treatments:
Amphotericin B Caspofungin Echinocandins Liposomal amphotericin B